Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

International Journal of Molecular Sciences

Laura Anido-Varela¹  Sandra Feijóo-Bandín¹  José Ramón González-Juanatey¹  Alana Aragón-Herrera¹  Manuel Otero-Santiago¹  Sandra Moraña-Fernández¹  Francisca Lago¹  Esther Roselló-Lletí²  Estefanía Tarazón²  Manuel Portolés²  Oreste Gualillo³ 

[1] Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS) and Xerencia de Xestión Integrada de Santiago de Compostela (XXIS/SERGAS), 15706 Santiago de Compostela, Spain;Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, 28029 Madrid, Spain;Laboratory of Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases, Institute of Biomedical Research (IDIS) and Xerencia de Xestión Integrada de Santiago de Compostela (XXIS/SERGAS), 15706 Santiago de Compostela, Spain;

关键词: SGLT2i;    inflammation;    M1/M2 macrophages;    NLRP3 inflammasome;    pyroptosis;    metaflammation;   

DOI  :  10.3390/ijms23105634

来源: DOAJ

【 摘 要 】

Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2. Beyond the regulation of glucose homeostasis, they resulted as being effective in different clinical trials in patients with heart failure, showing a strong cardio-renal protective effect in diabetic, but also in non-diabetic patients, which highlights the possible existence of other mechanisms through which gliflozins could be exerting their action. So far, different gliflozins have been approved for their therapeutic use in T2DM, heart failure, and diabetic kidney disease in different countries, all of them being diseases that have in common a deregulation of the inflammatory process associated with the pathology, which perpetuates and worsens the disease. This inflammatory deregulation has been observed in many other diseases, which led the scientific community to have a growing interest in the understanding of the biological processes that lead to or control inflammation deregulation in order to be able to identify potential therapeutic targets that could revert this situation and contribute to the amelioration of the disease. In this line, recent studies showed that gliflozins also act as an anti-inflammatory drug, and have been proposed as a useful strategy to treat other diseases linked to inflammation in addition to cardio-renal diseases, such as diabetes, obesity, atherosclerosis, or non-alcoholic fatty liver disease. In this work, we will review recent studies regarding the role of the main sodium-glucose co-transporter 2 inhibitors in the control of inflammation.

【 授权许可】

Unknown